Oncoteq is a clinical stage biotech focusing on oncology drug development reinforced by AI. It is founded and seeded by Cureteq and headquartered in Zug, Switzerland. The company pipeline currently comprises TEQ101 as a novel treatment option for advanced renal cell cancer with broad potential to expand into other indications, TEQ102 for CD30 expressing cancers, and TEQ103 with a completely novel mode of action for for oestrogen receptor positive cancers.
TEQ101
MetAP2 inhibition
Renal cell carcinoma
TEQ102
CD30
CD30+ Lymphomas
TEQ103
ER alpha
Breast cancer
For more information please refer to Oncoteq homepage
Do you want to know learn more about Oncoteq or the pipeline compounds?
Please reach out to us
